Eun Yang
Stock Analyst at Jefferies
(0.33)
# 4,188
Out of 4,918 analysts
34
Total ratings
25%
Success rate
-29.93%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $274.70 | +57.26% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $2.73 | +193.04% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $6.92 | +290.46% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.47 | +222.58% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $47.27 | -30.19% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.66 | +1,586.75% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $18.81 | +43.54% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.61 | +334.78% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.40 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.74 | +568.45% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $0.04 | +174,725.17% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.12 | +2,132.14% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.17 | +103.84% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $295.10 | -25.45% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $128.00 | +142.19% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $112.29 | -28.76% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $274.70
Upside: +57.26%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $2.73
Upside: +193.04%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $6.92
Upside: +290.46%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.47
Upside: +222.58%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $47.27
Upside: -30.19%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.66
Upside: +1,586.75%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $18.81
Upside: +43.54%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.61
Upside: +334.78%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.40
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.74
Upside: +568.45%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $0.04
Upside: +174,725.17%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.12
Upside: +2,132.14%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $17.17
Upside: +103.84%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $295.10
Upside: -25.45%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $128.00
Upside: +142.19%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $112.29
Upside: -28.76%